Institute for International Research

December 10 @12:30-2:00pm ET

Panel I - Not If, But When Personalized Medicine Is Made Possible, Then What Happens?

• Human Clinical Trials Processes: What are the social, public policy, and ethical dimensions?
• Building Appropriate Bridges to support Personalized Medicine:
• formal and informal 'partnerships'/collaborations across sectors (such as involving R&D Industry, HHS (especially FDA and NIH) Government, and Academia
• business alliances among companies; and
• international cooperation (e.g., via the EU's EMEA and CIOMS in interaction with 'partnerships' and business alliances
• Priorities?
  • In an era of obsession with healthcare costs, transparency, and access, how do we best determine what kinds of research to target in light of social, public policy and ethical considerations?
• Social Responsibility and Personalized Medicine
  • In addition to priority considerations, what are the social responsibilities involved with Personalized Medicine - such as public outreach, education and interactions with media - that industry, government and academia have?
• Information and Communication with the Public and Healthcare Professionals
  • What will physicians do differently based on results of diagnostic tests?
  • Will different therapy always lead to a better outcome?
  • What do we tell patients when a PM test identifies something that there is no treatment for, especially if it is a series/fatal diagnosis that a patient can receive by commercial tests without the advice of a physician?

Moderators:
Matthew Whalen, Ph.D., Principal, Impact LLC.
Mary Mease, R.Ph., M.P.H., Senior Director, Global Medical Affairs, Epidemiology and Health Outcomes, Quintiles

Panel Participants:
David B Clissold, M.A., J.D., Attorney at Law, Hyman, Phelps & McNamara P.C.
Stephen Friend, Ph.D., Senior Vice President, Molecular Profiling & Basic Cancer Research
Merck Research Labs, Merck & Co. Inc.
Douglas Peddicord, Ph.D., President, Washington Health Strategies Group, Oldaker, Belair & White
Michael N. Liebman, Ph.D., President/Managing Director, Strategic Medicine, Inc.
Chester "Bernie" Good, M.D., Physician, VA Medical Center